NRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.
NRx Pharmaceuticals highlighted a retrospective study presented at the ASCP conference showing IV ketamine had significantly higher remission (34% vs 26%) and response (63% vs 58%) rates than intranasal esketamine in treatment-resistant depression. The study, authored by Osmind Inc. and Yale University, analyzed 8,224 IV ketamine patients and 1,830 nasal esketamine patients, finding IV ketamine patients were 50% more likely to achieve remission (OR 1.51).
Key figures
- Drug Name
- NRX-100
- Response odds ratio
- 1.22
- Iv ketamine patients
- 8224
- Matched analysis set
- 3560
- Remission odds ratio
- 1.51
- Iv ketamine response rate
- 63%
- Nasal esketamine patients
- 1830
- Iv ketamine remission rate
- 34%
- Nasal esketamine response rate
- 58%
- Nasal esketamine remission rate
- 26%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.